Simplex Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-6,704
| Closed | -$1.86M | – | 8533 |
|
|
2025
Q1 | $1.81M | Buy |
6,704
+1,875
| +39% | +$482K | ﹤0.01% | 2127 |
|
|
2024
Q4 | $1.14M | Buy |
+4,829
| New | +$1.27M | ﹤0.01% | 2718 |
|
|
2024
Q3 | – | Sell |
-8,803
| Closed | -$2.29M | – | 8376 |
|
|
2024
Q2 | $2.14M | Buy |
+8,803
| New | +$1.39M | ﹤0.01% | 2135 |
|
|
2024
Q1 | – | Sell |
-2,916
| Closed | -$486K | – | 8754 |
|
|
2023
Q4 | $558K | Sell |
2,916
-3,929
| -57% | -$669K | ﹤0.01% | 3574 |
|
|
2023
Q3 | $1.21M | Buy |
+6,845
| New | +$1.31M | ﹤0.01% | 2492 |
|
|
2023
Q2 | – | Sell |
-13,723
| Closed | -$2.72M | – | 8871 |
|
|
2023
Q1 | $2.75M | Buy |
13,723
+4,846
| +55% | +$1.02M | ﹤0.01% | 1690 |
|
|
2022
Q4 | $2.11M | Buy |
8,877
+8,868
| +98,533% | +$1.89M | ﹤0.01% | 1825 |
|
|
2022
Q3 | $1K | Sell |
9
-1,068
| -99% | -$204K | ﹤0.01% | 9476 |
|
|
2022
Q2 | $157K | Buy |
+1,077
| New | +$153K | ﹤0.01% | 4924 |
|
|
2021
Q4 | – | Sell |
-15,991
| Closed | -$2.97M | – | 10384 |
|
|
2021
Q3 | $2.71M | Buy |
15,991
+707
| +5% | +$133K | ﹤0.01% | 1779 |
|
|
2021
Q2 | $2.59M | Buy |
15,284
+898
| +6% | +$132K | ﹤0.01% | 1842 |
|
|
2021
Q1 | $2.03M | Buy |
14,386
+6,311
| +78% | +$950K | ﹤0.01% | 1590 |
|
|
2020
Q4 | $1.05M | Buy |
8,075
+7,806
| +2,902% | +$1.04M | ﹤0.01% | 2491 |
|
|
2020
Q3 | $39K | Buy |
+269
| New | +$38.2K | ﹤0.01% | 5836 |
|
|
2020
Q2 | – | Sell |
-14,470
| Closed | -$1.95M | – | 7522 |
|
|
2020
Q1 | $1.57M | Buy |
+14,470
| New | +$1.67M | ﹤0.01% | 1478 |
|
|
2019
Q2 | – | Sell |
-2,772
| Closed | -$213K | – | 7022 |
|
|
2019
Q1 | $259K | Buy |
+2,772
| New | +$232K | ﹤0.01% | 3326 |
|
|
2018
Q1 | – | Sell |
-5,971
| Closed | -$770K | – | 6043 |
|
|
2017
Q4 | $758K | Sell |
5,971
-6,423
| -52% | -$807K | 0.03% | 509 |
|
|
2017
Q3 | $1.46M | Buy |
+12,394
| New | +$1.06M | 0.06% | 260 |
|
|
2017
Q2 | – | Sell |
-32,718
| Closed | -$2.09M | – | 6001 |
|
|
2017
Q1 | $1.68M | Buy |
32,718
+24,987
| +323% | +$1.15M | 0.07% | 241 |
|
|
2016
Q4 | $289K | Sell |
7,731
-1,025
| -12% | -$42.9K | 0.02% | 821 |
|
|
2016
Q3 | $593K | Sell |
8,756
-5,994
| -41% | -$423K | 0.04% | 440 |
|
|
2016
Q2 | $818K | Buy |
14,750
+7,648
| +108% | +$482K | 0.05% | 346 |
|
|
2016
Q1 | $445K | Buy |
+7,102
| New | +$472K | 0.04% | 499 |
|
|
2015
Q4 | – | Sell |
-4,335
| Closed | -$402K | – | 5318 |
|
|
2015
Q3 | $348K | Sell |
4,335
-3,548
| -45% | -$394K | 0.03% | 589 |
|
|
2015
Q2 | $944K | Buy |
+7,883
| New | +$942K | 0.08% | 227 |
|
|
2015
Q1 | – | Sell |
-853
| Closed | -$86.4K | – | 4895 |
|
|
2014
Q4 | $83K | Buy |
+853
| New | +$79K | 0.01% | 1034 |
|
Other funds holding ALNY
VPM
VCM
Simplex Trading's ALNY Position: Q2 2025 in Review
Simplex Trading sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 6,704 shares — an estimated $1.86M sold.
Simplex Trading first reported a position in ALNY in Q4 2014 and held it in 26 quarters. The position peaked at $2.75M in Q1 2023. 654 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.
- Simplex Trading reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Simplex Trading sold 6,704 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $1.86M.
- Simplex Trading first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 26 quarters.
- Simplex Trading's Alnylam Pharmaceuticals position peaked at $2.75M in Q1 2023.
- 654 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.
Based on Simplex Trading's 13F filing for Q2 2025, filed 5 Aug 2025.